



Nexstim Receives System Order from US University

Press release, Helsinki, 28 March 2025 at 9 AM (EET)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 5+ system from a university located in southern United States.

The NBS (Navigated Brain Stimulation) 5+ is a system configuration that enables the delivery of both diagnostic and therapeutic applications in the same device. In diagnostics, the system is FDA-approved for non-invasive, pre-surgical mapping of motor and speech cortices prior to neurosurgery. The system also has FDA-clearance for the treatment of Major Depressive Disorder (MDD).

The customer is new to Nexstim and will use the system in neurosurgery as well as neuroscience and therapy.

Mikko Karvinen, CEO of Nexstim, comments: *"Our products offer a one-of-a-kind opportunity for healthcare professionals to utilize one product across departments. In addition to being the only FDA-cleared navigated transcranial magnetic stimulation system for pre-surgical mapping of the speech and motor cortices of the brain, the NBS 5+ can also be used to treat depression patients as well as for research purposes."*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com